Skip to content
In conversation with... Steven Horwitz episode artwork

Oct 30, 2024 15 min

In conversation with... Steven Horwitz

from Listen to The Lancet Oncology Hosted by The Lancet

Dr Steven Horwitz (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a phase 1 study of valemetostat in relapsed or refractory non-Hodgkin lymphoma and a phase 2 study of valemetostat in relapsed or refractory peripheral T-cell lymphoma.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

In conversation with... Steven Horwitz

0:00 15:07

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Listen to The Lancet Oncology?

This episode is 15 minutes long.

When was this Listen to The Lancet Oncology episode published?

This episode was published on October 30, 2024.

Can I download this Listen to The Lancet Oncology episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.